GlassScriptPhysician profile
Michel Kourie
NPI 1083606008
$8,937.92
in general payments reported to CMS, 2019-2025
50 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $689 · 2021: $1,594 · 2022: $1,596 · 2023: $1,229 · 2024: $1,064 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,536.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,554.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,076.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $869.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $863.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $328.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.50 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $273.96 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.79 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $243.62 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $226.72 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $220.87 | 2019-2025 | |
| Abbott Laboratories | $214.51 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $195.50 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.82 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $155.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Kourie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.